Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




New Data on Blood Clot Remover

By HospiMedica staff writers
Posted on 18 Jul 2005
Data from a multicenter trial of 141 ischemic stroke patients ineligible for tissue plasminogen activator (tPA) treatment have shown that 48% had their blood flow successfully restored by a new device that removes blood clots from the brain.

The study involved the use of the Merci Retriever system, developed by Concentric Medical (Mountain View, CA, USA). More...
The participating doctors navigated the Merci Retriever into the brain, using standard catheterization techniques. Under radiologic guidance, they inserted a catheter into the groin and routed it through the blood vessels leading to the brain. The Merci Retriever was then introduced through the catheter directly to the targeted area. Once in position, the device was deployed to engage and ensnare the clot, pulling it back through the catheter and out of the body.

The study's authors noted that 48% was a significantly higher number than the established historical control of 18%. In addition, they found that patients with successful recanalization had good neurologic outcomes with less mortality, compared to patients with unsuccessful recanalization. The results were reported in the July 2005 issue of Stroke. The Merci Retriever has been cleared by the U.S. Food and Drug Administration (FDA).

"These data reveal that the Merci Retriever showed success in patients with severe strokes who would otherwise have died or suffered severe disability and for whom, before this device was available, there was no approved alternative treatment,” noted Dr. Gary Duckwiler, investigator for the Merci study at the University of California at Los Angeles (UCLA, USA). "Also important to note is that there were very few complications, such as hemorrhages, which can create serious problems in cases where other treatments such as ‘clot busting' drugs are used. Ultimately, this new tool could very well revolutionize stroke treatment as we know it.”




Related Links:
Concentric Medical
UCLA

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Bipolar Coagulation Generator
Aesculap
Adjustable Mobile Barrier
M-458
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.